Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: Press Releases

ISTH Announces Major Plans for Guideline and Educational Program Developments in Hemophilia in 2019

Thursday, December 20, 2018   (0 Comments)
Share |

CHAPEL HILL, NC, USA – December 12, 2018 – The International Society on Thrombosis and Haemostasis (ISTH) is pleased to announce major plans for guideline and educational program developments in hemophilia in 2019.

With the increasing global availability of novel therapies for the treatment of hemophilia, ISTH identified the need for clinical practice guidelines as well as companion educational programs that will increase critical knowledge and offer practical, evidence-based recommendations to support clinical decision making that ultimately improve patient care.

The clinical practice guidelines will specifically address the use of extended half-life recombinant factor VIII and factor IX concentrates as well as non-replacement therapy vs. standard treatments to assist physicians to make the most informed treatment decisions and correctly use these new products in the routine clinical care of hemophilia.

Development will begin in early 2019 in collaboration with a leading guidelines development group of international reputation, and will follow strict guideline development methodology. 

Following the completion of the guidelines, the ISTH plans to expand upon its best-in-class educational resources by producing companion programs based on the new guidelines.

Additionally, the ISTH is pleased to announce that it is in the beginning stages of the development of an educational program on gene therapy in hemophilia, with the focus on preparing healthcare professionals for the advent of gene therapy as another treatment option of the future. Currently in educational road-map development, the program is expected to be first introduced at the ISTH 2019 Congress, July 6-10, 2019, in Melbourne, Australia.

“With the treatment landscape in hemophilia rapidly evolving and clinicians around the world being challenged to keep current with the latest scientific developments and clinical advancements, developing state-of-the-art clinical practice guidelines and education programs is critical to ensure best patient care”, said Flora Peyvandi, MD, PhD, Chair of the ISTH Education Committee.

“As the leading international medical-scientific professional society in thrombosis and hemostasis, the ISTH already unites the pre-eminent scientists and clinicians and is therefore best positioned to lead these important programs," said Claire McLintock, MBChB, FRACP, FRCPA, President of ISTH. As we know from our recently conducted educational needs assessment, our global community is looking towards ISTH to continue and further strengthen its over five-decades-long role at the forefront of the major contributions and the advancement in our field. The ISTH looks forward to assisting the international community in navigating these exciting times of novel treatment opportunities."

More detailed information on the projects will be provided in early 2019.

 

About the ISTH

Founded in 1969, the ISTH is the leading worldwide not-for-profit organization dedicated to advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. ISTH is an international professional membership organization with more than 5,000 clinicians, researchers and educators working together to improve the lives of patients in more than 100 countries around the world. Among its highly regarded activities and initiatives are education and standardization programs, research activities, meetings and congresses, peer-reviewed publications, expert committees and World Thrombosis Day on 13 October. Visit ISTH online at www.isth.org.


Membership Management Software Powered by YourMembership  ::  Legal